OBX-115 plus Acetazolamide for Melanoma

Phase-Based Progress Estimates
MD Anderson Cancer Center, Houston, TX
Melanoma+2 More
OBX-115 - Drug
All Sexes
What conditions do you have?

Study Summary

To find the recommended dose of OBX-115 in combination with acetazolamide that can be given to patients with metastatic melanoma previously treated with immune checkpoint inhibitors.

Eligible Conditions

  • Melanoma
  • Metastatic Melanoma
  • Tumors

Treatment Effectiveness

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: through completion of study, an average of 1 year

Year 1
To establish progression free survival (PFS)

Trial Safety

Trial Design

1 Treatment Group

OBX-115 plus Acetazolamide
1 of 1
Experimental Treatment

30 Total Participants · 1 Treatment Group

Primary Treatment: OBX-115 plus Acetazolamide · No Placebo Group · Phase 1

OBX-115 plus AcetazolamideExperimental Group · 6 Interventions: OBX-115, Fludarabine Phosphate, Cyclophosphamide, Mesna, Acetazolamide, Furosemide · Intervention Types: Drug, Drug, Drug, Drug, Drug, Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
Fludarabine Phosphate
Completed Phase 3
Completed Phase 3
Completed Phase 2
Completed Phase 4
Completed Phase 4

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: through completion of study, an average of 1 year
Closest Location: MD Anderson Cancer Center · Houston, TX
Photo of MD Anderson Cancer Center  1Photo of MD Anderson Cancer Center  2Photo of MD Anderson Cancer Center  3
2004First Recorded Clinical Trial
75 TrialsResearching Melanoma
520 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are male or female
• ANC ≥ 1000/mm3.
• Hemoglobin ≥ 8.
• Patients with liver metastases may have LFT ≤ 5.0 x ULN.
• Calculated creatinine clearance (Cockcroft-Gault) ≥ 50.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.